BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study
Methods: Four hundred and sixty-one adult subjects with migraine were randomised to one of five treatments, the oral antagonist at the calcitonin gene-related peptide (CGRP) receptor BI 44370 TA (50 mg, 200 mg, 400 mg), active comparator eletriptan 40 mg or placebo. The analysis included 341 subject...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | angličtina |
| Vydáno: |
2010
|
| On-line přístup: | https://doi.org/10.1177/0333102410388435 https://journals.sagepub.com/doi/pdf/10.1177/0333102410388435 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|